Skip to main content

Table 1 Patient demographics and baseline characteristics (ITT Population)

From: Fluticasone propionate/salmeterol 250/50 μg versus salmeterol 50 μg after chronic obstructive pulmonary disease exacerbation

  FP/SAL 250/50 μg (N = 314) SAL 50 μg (N = 325) Total (N = 639)
Age, years 63.1 (9.15) 62.7 (9.30) 62.9 (9.22)
Female sex, n (%) 140 (45) 151 (46) 291 (46)
White race, n (%) 284 (90) 300 (92) 584 (91)
Duration of COPD, years 7.0 (5.7) 6.6 (5.2) 6.8 (5.4)
COPD type    
Chronic bronchitis (%) 114 (36) 129 (40) 243 (38)
Emphysema (%) 121 (39) 119 (37) 240 (38)
Both (%) 79 (25) 77 (24) 156 (24)
Smoking pack-years 52.0 (30.0) 56.3 (33.4) 54.2 (31.8)
Body mass index, kg/m2 28.0 (6.85) 28.3 (6.95) 28.2 (6.90)
Baseline pre-bronchodilator FEV1, L 1.08 (0.476) 1.14 (0.467) 1.11 (0.472)
Baseline % predicted FEV1 38.5 (14.82) 41.2 (16.85) 39.9 (15.93)
FEV1% reversibility 15.1 (23.79) 12.1 (16.69) 13.6 (20.52)
Reversibility    
Non-reversible (%) 232 (74) 245 (76) 477 (75)
Reversible (%) 80 (26) 79 (24) 159 (25)
  1. Mean (SD) unless otherwise stated. Reversibility testing was performed following subject self-administration of four puffs (360 μg) albuterol. COPD = chronic obstructive pulmonary disease; FEV1= forced expiratory volume in 1 second; FP = fluticasone propionate; ITT = intent-to-treat; SAL = salmeterol; SD = standard deviation.